

Clinic address:
Kyiv, Nikolsko-Slobodskaya str.
2-B (Levoberezhnaya metro station)

Tel.:
+38 (044) 516-7244, 541-0920
t/f.: +38 (044) 4-939-839

I.S. Markov.

Clinical experience of applying of Cymeven (Ganciclovir) for medical treatment of cytomegaloviral infection inherent to immunocompetent patients.

Summary

43 patients (17 children at the age from 4 to 12 or 39,5% and 26 adults or 60,5%) with chronic recurrent cytomegalovirus infection in the stage of reactivation with replicative virus activity were observed. All patients were immunocompetent persons: they had no HIV-infection, they have been subjected neither to immunosuppressive and X-ray therapy nor chronic hemodialysis, they did not belong to groups of risk regarding their sexual behaviour. As indication for application of a combined antiviral therapy (Cymeven + anti-CMV human immunoglobulin + recombinant α -2-interferon + Erbisol) were clinically manifested form of CMV-infection (syndrome of chronic tiredness, episyndrom and pharmaco-resistant form of epilepsy, disseminated sclerosis, eye-lesion – back, front panuveitis), as well as clinically asymptomatic DNA-positive form of chronic CMV-infection inherent to 7 non-gravidas with complicated obstetrical anamnesis. The course of medical treatment by means of Cymeven was relatively short – from 3–4 to 8–10 weeks and total dose of the intravenously injected medication (39% of patients – in combination with capsule form) – from 180 up to 210 mg/kg. In 40 cases (93 \pm 3)% there was achieved quick and stable (during the time less than 3,5 years of katamnestic observation) positive clinical and/or laboratory result after one course of antiviral therapy. Clinical effectiveness of the treatment by means of Cymeven was confirmed by laboratory results of negativation of the virus DNA in various biosubstrata. The above effectiveness is determined by means of method of PCR. There was given a list of by-effects of the medication and there was also noted the complete regression of the mentioned by-effects after reduction of the dose – from 10mg/kg per day to 6 mg/kg per day or after completion of the therapy.